OPCML and cholangiocarcinoma: In conclusion, detection of serum cfDNA methylation of OPCML and HOXD9 which served as a differential biomarker could be clinically helpful to prevent misdiagnosis between CCA and other biliary diseases due to its simplicity, less invasiveness, and clinically practical method.